mk-4334
Cognitive Impairment Associated With Schizophrenia
Merck Sharp & Dohme LLCPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
144 Active assets in the Cognitive Impairment Associated With Schizophrenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
Asenapine Noven Pharmaceuticals, Inc. | Phase 4 | BBB |
Xanomeline European Group for Research In Schizophrenia | Phase 4 | BBB |
TROSPIUM European Group for Research In Schizophrenia | Phase 4 | BBB |
Opc-34712 Humanis Saglık Anonim Sirketi | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
mk-4334 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →